Recreational vs. Competitive Cycling in a Male Cyclist with LVH and Progressive LGE on Testosterone Therapy
This cyclist should immediately discontinue competitive cycling and limit activity to low-intensity recreational cycling only, given the concerning progression of late gadolinium enhancement (4%→12%) which signals pathological myocardial fibrosis that substantially increases risk of ventricular arrhythmias and sudden cardiac death with high-intensity endurance exercise.
Critical Context: This is NOT Physiological Athlete's Heart
The progressive increase in LGE from 4% to 12% is the decisive red flag here. This pattern indicates pathological myocardial scarring, not benign athletic remodeling. The 2025 AHA/ACC guidelines emphasize that sudden cardiac arrest risk in cardiomyopathy increases with higher scar burden 1. Recent cardiac MRI research confirms that approximately one-third of competitive cyclists develop focal non-ischemic LGE, but those with non-RVIP (right ventricular insertion point) LGE show adverse remodeling with reduced RV ejection fraction and elevated troponin—a distinct pathological phenotype 2. Progressive LGE is never physiological.
Additionally, testosterone therapy compounds this risk. The FDA label warns that testosterone can cause cardiovascular complications 3, and recent case reports document testosterone-induced heart failure with LV dysfunction in athletes 4. The combination of endurance cycling, LVH, progressive fibrosis, and exogenous testosterone creates a perfect storm for malignant arrhythmias.
Defining Competitive vs. Recreational Cycling
Competitive Cycling (UNACCEPTABLE for this patient):
- Training volume: >9-18 hours/week, often exceeding 18 hours/week for elite cyclists 5
- Intensity: High-intensity intervals, threshold training, race-pace efforts
- Competition: Organized races, time trials, criteriums, road races
- Physiological demands: Sustained high cardiac output, peak heart rates >85-90% maximum, VO2max efforts
- Cardiac stress: Mixed eccentric-concentric hypertrophy with wall thickness increases up to 29% and relative wall thickness increases of 19% 6
Recreational Cycling (POTENTIALLY ACCEPTABLE with strict limitations):
- Training volume: ≤3 hours/week of low-intensity activity 5
- Intensity: Conversational pace, heart rate <70% maximum, no intervals or threshold work
- No competition: Casual rides, commuting, social cycling only
- Physiological demands: Minimal cardiac stress, sustainable aerobic activity
- Monitoring required: Regular cardiac surveillance with repeat CMR, ECG, Holter monitoring
Specific Recommendations for This Patient
Immediate Actions:
- Discontinue competitive cycling entirely - The 2025 AHA/ACC guidelines state that athletes with cardiomyopathy features and increasing scar burden face heightened sudden cardiac death risk with endurance sports 1
- Stop testosterone therapy - Exogenous testosterone increases cardiovascular risk and may accelerate pathological remodeling 3, 4
- Comprehensive cardiomyopathy evaluation including:
- Genetic testing for DCM, HCM, and ACM variants (LMNA, DSP, FLNC, PKP2) 1
- 24-hour Holter monitoring for ventricular arrhythmias
- Exercise stress testing to assess for exercise-induced arrhythmias
- Repeat CMR in 3-6 months to assess LGE progression
Exercise Prescription (if cleared after evaluation):
- Maximum 3 hours/week of low-intensity cycling
- Heart rate cap: <70% of maximum (roughly 105-120 bpm for a 40-year-old)
- No hills, intervals, or group rides that encourage competitive behavior
- Stationary bike preferred initially for controlled environment
- Wearable heart rate monitor mandatory to enforce intensity limits
Ongoing Surveillance:
- Cardiac MRI every 6-12 months to monitor LGE progression
- Echocardiography every 3-6 months to assess ventricular function
- Annual Holter monitoring and exercise stress testing
- Immediate cessation if LGE increases further, ventricular arrhythmias develop, or symptoms emerge
Critical Pitfalls to Avoid
Do not assume this is benign athlete's heart. While cyclists commonly develop eccentric LVH with increased LV mass and volumes 7, 8, 6, progressive LGE distinguishes pathological from physiological remodeling. The 2019 European guidelines specifically state that athletes with impaired LV systolic function and/or frequent ventricular arrhythmias should abstain from competitive sports 9.
Do not allow "just one more season." The 2025 AHA/ACC guidelines emphasize that endurance sports participation in cardiomyopathy patients—particularly with high scar burden—substantially increases risk of ventricular arrhythmias, structural disease progression, and sudden cardiac death 1. The risk-benefit calculation clearly favors restriction.
Do not ignore the testosterone factor. Anabolic-androgenic steroids are strongly associated with LV dysfunction, heart failure, and arrhythmias 4. Continuation while cycling competitively is particularly dangerous.
The Bottom Line
**Recreational cycling at low intensity (≤3 hours/week, <70% max HR) may be acceptable after comprehensive evaluation rules out high-risk cardiomyopathy genotypes and confirms absence of ventricular arrhythmias.** Competitive cycling (>9 hours/week, high-intensity training, racing) is unacceptable given progressive myocardial fibrosis. This distinction prioritizes mortality and quality of life over athletic performance. Shared decision-making should occur only after full disclosure that continued high-intensity endurance exercise with progressive LGE carries substantial sudden death risk 1.